---
format: 
  revealjs:
    hash-type: number
    transition: fade
    auto-stretch: false
    self-contained: true
    height: 900
    width: 1600
    footer: ""
    slide-number: c/t
knitr: 
  opts_chunk: 
    echo: false

---

##  {}

::: {style="position: absolute; left: 180px; top: 200px; height: 525px; width: 1200px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 15px 0px 0px #6C3483; border-radius: 5px;"}
[Leveraging real-world data and randomised controlled trials to advance personalised medicine]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px"}

<br>

[Ignacio Leiva-Escobar]{style="font-size: 50px; font-weight: bold; color: #808080"} <br> 
[MSc Epidemiology - Charité Universitätsmedizin Berlin]{style="font-size: 25px;color: #808080"}  <br> 
[MSc Health Data Science - LSHTM]{style="font-size: 25px;color: #808080"} 

[2023]{style="font-size: 50px;font-weight: bold;"}
:::


## {background-color="#581845"}

<p style="margin:700px;"></p>

[Background]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}
    
## [Randomised Controlled Trials]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}

\

- `RCT III` are Gold Standard for Drug approval (Efficacy) 
- Designed to generate internally valid treatment effect


  - Randomization/Masking
  

  - Monitoring and follow-up
- Included in clinical guidelines 
- Used by Health care providers

## [Trial population]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #581845"}
::: columns
::: {.column width="20%"}

\ 

::: {style="position: absolute; left: 10px; top: 200px; height: 120px; width: 410px; border:0.2px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -5px 0px 0px 0px #6C3483; border-radius: 5px;"}

[Random sample]{style="font-size: 35px; font-weight: bold;color: #000000"}
[$ATE_{trial\ population} = ATE_{target\ population}$]{style="font-size: 25px; font-weight: bold; color: #000000"}
:::



\ 

::: {style="position: absolute; left: 10px; top: 500px; height: 120px; width: 410px; border:0.2px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -5px 0px 0px 0px #6C3483; border-radius: 5px;"}

[No random sample]{style="font-size: 35px; font-weight: bold;color: #000000"}
[$ATE_{trial\ population} \neq ATE_{target\ population}$]{style="font-size: 25px; font-weight: bold; color: #000000"}

:::

:::
::: {.column width="80%"}

![](targetpopulation.jpg){width="80%" height="80%" fig-align="center"}

:::
:::

## [External &  Internal validity ^[Raymond S. Greenberg, Medical Epidemiology, Third Edition]]{style="font-size: 67px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}


::: {style="position: absolute; left: 30px; top: 200px; height: 370px; width: 600px; border:0.2px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -7px 0px 0px 0px #85929e; border-radius: 5px;"}

[Internal Validity]{style="font-size: 35px; font-weight: bold;color: #000000"}

\

[“The extent to which the results of an investigation accurately reflect the situation of the study  population”]{style="font-size: 35px; font-weight: bold; color: #797474"}
:::




::: {style="position: absolute; left: 800px; top: 200px; height: 370px; width: 600px; border:0.2px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -7px 0px 0px 0px #c39bd3; border-radius: 5px;"}

[External Validity]{style="font-size: 35px; font-weight: bold;color: #000000"}

\ 

[“The extent to which the results of a study are applicable to other populations”]{style="font-size: 35px; font-weight: bold; color: #797474"}

:::

## External validity can be divided into {auto-animate=true auto-animate-easing="ease-in-out"}

::: {style="position: absolute; left: 180px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 0px; padding-right: 0px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px;"}



::: {.r-hstack}
::: {data-id="box1" auto-animate-delay="0" style="background: #c39bd3; width: 200px; height: 150px; margin: 10px;"}

[Target A]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 35px;"}

:::

::: {data-id="box2" auto-animate-delay="0.1" style="background: #344c5c; width: 100px; height: 150px ;margin-right:-280px; "}
:::



:::
:::

::: {style="position: absolute; left: 710px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 0px; padding-left: 0px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px; "}


::: {.r-hstack}

::: {data-id="box2" auto-animate-delay="0.1" style="background: #344c5c; width: 100px; height: 150px; margin-left:-280px;"}

 [Trial]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 5px;"}

:::

::: {data-id="box1" auto-animate-delay="0" style="background: #85929e; width: 200px; height: 150px; margin: 10px;"}

[Target B]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 35px;"}

:::


:::
:::




## External validity can be divided into {auto-animate=true auto-animate-easing="ease-in-out"}
::: {style="position: absolute; left: 200px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-right: 0px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px; margin: 0px; float: left"}

[Generalisability]{style="font-size: 35px; font-weight: bold;color: #000000; text-align: center;padding-left: 130px;"}

\

::: {.r-stack}
::: {data-id="box1" style="background: #c39bd3; width: 350px; height: 350px; border-radius: 200px;"}
[Target A]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 110px;"}
:::

::: {data-id="box2" style="background: #344c5c; width: 150px; height: 150px; border-radius: 100px;"}
[Trial]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 40px;"}
:::

:::
:::
::: {style="position: absolute; left: 800px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px;"}

[Transportability]{style="font-size: 35px; font-weight: bold;color: #000000; text-align: center;padding-left: 110px;"}

\

::: {.r-hstack}
::: {data-id="box1" style="background: #85929e; width: 350px; height: 350px; border-radius: 200px;"}
[Target B]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 110px;"}
:::

::: {data-id="box2" style="background: #344c5c; width: 150px; height: 150px; border-radius: 200px;left: 1200px;"}
[Trial]{style="font-size: 35px; font-weight: bold; color: #ffffff;padding-left: 40px;"}
:::


:::
:::


## How can we address this issue {auto-animate=true}

\

> [Trial design approaches]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} 

  - Doubly randomized trials
  - Pragmatic trials
\ 

. . .

> [Analytic approaches]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} 

  - Observational analyses / target trial emulation
  - Generalisability/transportability using trial and observational data
  
## {background-color="#471337"}


<p style="margin:700px;"></p>

[Generalisability/transportability analyses]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}


## [Check the]{style="font-size: 67px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "} Identifiability conditions 

::: {style="position: absolute; left: 330px; top: 150px; height: 250px; width: 1100px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}

[(I) Consistency of potential outcomes]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #4a235a"}

[(II) Mean exchangeability in the trial]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #4a235a"}

[(III) Positivity of treatment assignment]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #4a235a"}
:::

::: {style="position: absolute; left: 20px; top: 150px; height: 250px; width: 230px; background-color: #4a235a; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}

\

[RCT]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

[Internal Validity]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

:::

. . .

::: {style="position: absolute; left: 330px; top: 500px; height: 250px; width: 1100px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #fab724; border-radius: 5px; border:0.2px solid #D9D9D9"}
[(IV) Conditional exchangeability for study selection* ]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}

[(V) Positivity of trial participation*]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}

[Additionally:]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}
[(1) There are no unmeasured variables associated with treatment effect and trial sample selection 
(2) Well-specify model]{style="font-size: 25px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}



:::


::: {style="position: absolute; left: 20px; top: 500px; height: 250px; width: 230px; background-color: #fab724; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #fab724; border-radius: 5px; border:0.2px solid #D9D9D9"}

\

[Extend RCT]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

[External Validity]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

:::

## How should the _target population_ be selected?
 \
 
Based on the research question. 

However, it might be limited by the available source of target population data  

 - _Characteristics of the individuals (especially EM)_ 
 - _How variable measurements were ascertained (compared to RCT)_

::: {.callout-tip title="Example"}
## Example
 - Patients need to fulfil inclusion/exclusion criteria*

 - Have measurements of relevant effect modifiers identified
:::

## Require patient-data level

\ 
 
> [Trial population:]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}  covariates, exposure, outcome

\

> [Target population:]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}  covariates, outcome*

\ 

Include as many potential [effect modifiers]{style="font-size: 45px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} as possible

   - matter-knowledge 
   - subgroups analysis 
   - Previous evidence

## Estimation of _average treatment effect_ in the target population

\

> [Inverse probability (IP) weighting]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} estimators that rely on modelling the probability of  participation in the trial

\

. . .

> [Outcome model-based]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} estimators that rely on modelling the expectation of the outcome

\ 

. . .

> [Augmented IP weighting]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} estimators that rely on modelling both the expectation of the outcome and the probability of participation in the trial. 

## {background-color="#471337"}


<p style="margin:700px;"></p>

[Inverse probability weighting estimators]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}

## Inverse probability weighting estimators

::: {style="position: absolute; left: 20px; top: 200px; height: 380px; width: 420px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 10px 0px #fab724; border-radius: 5px; border:0.2px solid #D9D9D9"}
IPW estimators model the [probability of participation in the trial]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}  (sampling) using participant characteristics, similar to the propensity score 
:::

::: {style="position: absolute; left: 560px; top: 200px; height: 380px; width: 420px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 10px 0px #fb92a4; border-radius: 5px; border:0.2px solid #D9D9D9"}
Trial  population is used to create a [new target population]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #B84C65"} (re-weighted trial participants) with the same distribution of the target population
:::

::: {style="position: absolute; left: 1100px; top: 200px; height: 380px; width: 420px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
It can be done using Logistic regression or machine learning methods
Use the [outcome]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #9B4EBB"} of the weighted trial population in the analysis
:::



## It looks like

<br>

```{mermaid}
%%| fig-width: 10
%%{init: {'themeVariables': { 'primaryColor': '#ff0000',"fontSize": "10px"}}}%%
        graph LR
          A[Target population] -->|Covariates| C(Model)
          B[Trial population] -->|Covariates <br>outcome <br> treatment| C(Model)
          C --> D[Re-weighted <br> trial population]
          

```


## {background-color="#471337"}


<p style="margin:700px;"></p>

[Outcome-model based estimators]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}

## [Outcome-model based estimators]{style="font-size: 67px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}

\

 - Use trial data to build a prediction model.
 - Recommended building one model for [each arm]{style="font-size: 43px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} to better capture effect modification over baseline covariates 
 - Check the model specification
 
\

. . .

::: {.callout-tip title="Example"}
## Benefit over IPW estimators
the model can be applied to a new target population without re-weighting each time
:::
## {}

![](Shin/title.tiff){width="950" height="420" fig-align="center"}

<br>

::: {.callout-important}

## Aim

To predict the ATE of dabigatran vs warfarin on stroke/systemic embolism among patient patients with atrial Fibrillation in US Medicare beneficiaries 
:::

## [Identify the target population]{style="font-size: 67px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "}

<br>

![](Shin/diagram.tiff){width="1200" height="600" fig-align="center"}

::: {style="position: absolute; left: 380px; top: 800px; height: 50px; width: 150px; background-color: #ffffff; padding: 20px; padding-left: 10px; box-shadow: 0px 0px 10px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
[Trial population]{style="font-size: 20px; font-weight: bold; line-height: 0.5px; margin: 0px; color: #4a235a"}
:::

::: {style="position: absolute; left: 860px; top: 800px; height: 50px; width: 150px; background-color: #ffffff; padding: 20px; padding-left: 10px; box-shadow: 0px 0px 10px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
[$1^{st}$ Target pop.]{style="font-size: 20px; font-weight: bold; line-height: 0.5px; margin: 0px; color: #4a235a"}
:::

::: {style="position: absolute; left: 1200px; top: 800px; height: 50px; width: 150px; background-color: #ffffff; padding: 20px; padding-left: 10px; box-shadow: 0px 0px 10px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
[$2^{nd}$ Target pop.]{style="font-size: 20px; font-weight: bold; line-height: 0.5px; margin: 0px; color: #4a235a"}
:::

## Identify effect modifiers to be included in the model


<br>

![](Shin/EM.tiff){width="1200" height="600" fig-align="center"}

## Identify effect modifiers to be included in the model

<br>

![](Shin/table.tiff){width="1000" height="700" fig-align="center"}


## Prediction models^[equivalent to counterfactual probabilities of the outcomes had they been exposed to dabigatran or warfarin]

<br>

```{mermaid}
%%| fig-width: 10
%%{init: {'themeVariables': { 'primaryColor': '#ff0000',"fontSize": "10px"}}}%%
        graph LR
          A[Target population] --> B(Warfarin Model)
          A[Trial population] --> C(Dabigatran Model)
          C --> D[Risk Dabigatran]
          B --> E[Risk Warfarin]
          D --> F[RD or RR]
          E --> F

```

## {}
![](Shin/table2.tiff){width="1400" height="700" fig-align="center"}


## [Discussion]{style="font-size: 67px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "}

<br>

> Populations had different distributions of some covariates

<br>

> RR and RD for Stroke/SE were similar between the target and trial population as CHADS2 score strongly predicted Stroke/SE 

<br>

> RWE (Observed) study might differ in how the outcome was ascertained and also the presence of confounding. [Does this enable us to compare it with the results from the prediction?]{style="font-size: 40px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "} 

## Strength of this approach

<br>

> __Outcome model-based prediction__ requires only one-time model development in a trial, and the same model can be used in any target population that overlaps with the trial population. 

<br>

> The models are built from the trial data. Thus, confounding, differences in outcome ascertainment and follow-up are not an issue (typical challenges in observational studies).

## Limitations

<br><br><br><br>

::: {style="position: absolute; left: 10px; top: 140px; height: 120px; width: 1400px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -5px 0px 0px 0px #6C3483; border-radius: 5px;"}
Avaibablitiy, distribution, and acertaintemnt of the covariates (for both trial and target population)
:::

 - [e.g., Leave out and relevant effect modifier that higly predict the outcome might understamate the predicted risk]{style="font-size: 30px; color: #808080"}
 
 <br><br><br><br><br>
 
::: {style="position: absolute; left: 10px; top: 500px; height: 120px; width: 1400px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -5px 0px 0px 0px #6C3483; border-radius: 5px;"}

 Those models cannot extrapolate estimates to target populations with characteristics explicitly excluded from the trial. 
:::
 - [e.g., RE-LY trial excluded individuals with heart valve disorders or active liver disease which might be associated with the increased risk of stroke or bleeding. Then, apply a developed model to no eligible trial participant model’s performance cannot be guaranteed]{style="font-size: 30px; color: #808080"}
 
 
## Advancing to personalised medicine

<br>

> These methods enable us to generalise/transport ATE (ITE) from RCTs to clinical practice settings.

<br>

> They can be used in conjunction with observational studies, including target trial emulation to obtain target population estimates.

<br>

> Outcome-based models show promise in predicting treatment effects in various target populations with different individual characteristics.


##  {}

::: {style="position: absolute; left: 180px; top: 200px; height: 525px; width: 1200px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 15px 0px 0px #6C3483; border-radius: 5px;"}
[Leveraging real-world data and randomised controlled trials to advance personalised medicine]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px"}

<br>


[2023]{style="font-size: 50px;font-weight: bold;"}
:::


